Arjan Barendregt

Introduction Click to copy section linkSection link copied! Charge detection mass spectrometry (CDMS) has emerged as a distinctive approach to characterize heterogeneous, high-mass assemblies such as viruses, vaccines, and heavily glycosylated therapeutic proteins. (1,2) These large and often polydisperse samples typically display unresolvable mass spectra in conventional ensemble MS, hampering charge assignment and thus mass determination.

Introduction Click to copy section linkSection link copied! Charge detection mass spectrometry (CDMS) has emerged as a distinctive approach to characterize heterogeneous, high-mass assemblies such as viruses, vaccines, and heavily glycosylated therapeutic proteins. (1,2) These large and often polydisperse samples typically display unresolvable mass spectra in conventional ensemble MS, hampering charge assignment and thus mass determination.

Introduction Click to copy section linkSection link copied! Recombinant adeno-associated viruses (rAAVs) are extensively used for gene therapy due to their favorable properties (e.g., nonpathogenicity, low immunogenicity, broad tropism, and long-term expression). (1−3) The preparation of therapeutic rAAVs is hampered by the unwanted coproduction of empty capsids that do not contain the single-stranded DNA (ssDNA) gene of interest.